Genexine Inc - Asset Resilience Ratio

Latest as of September 2025: 3.45%

Genexine Inc (095700) has an Asset Resilience Ratio of 3.45% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 095700 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩12.65 Billion
≈ $8.57 Million USD Cash + Short-term Investments

Total Assets

₩366.23 Billion
≈ $248.19 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2009–2024)

This chart shows how Genexine Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 095700 total asset value.

Liquid Assets Composition Over Time

This chart breaks down Genexine Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of Genexine Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩12.65 Billion 3.45%
Total Liquid Assets ₩12.65 Billion 3.45%

Asset Resilience Insights

  • Limited Liquidity: Genexine Inc maintains only 3.45% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Genexine Inc Industry Peers by Asset Resilience Ratio

Compare Genexine Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
ALK-Abelló A/S
CO:ALK-B
Biotechnology 0.98%
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
Biotechnology 6.89%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
BB Biotech AG
SW:BION
Biotechnology 92.97%
Soleno Therapeutics Inc
NASDAQ:SLNO
Biotechnology 20.15%
Nanobiotix
NASDAQ:NBTX
Biotechnology 4.71%
Wuhan Keqian Biology Co Ltd
SHG:688526
Biotechnology 19.42%
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590
Biotechnology 10.55%

Annual Asset Resilience Ratio for Genexine Inc (2009–2024)

The table below shows the annual Asset Resilience Ratio data for Genexine Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 9.30% ₩32.08 Billion
≈ $21.74 Million
₩345.04 Billion
≈ $233.83 Million
-7.83pp
2023-12-31 17.12% ₩64.48 Billion
≈ $43.70 Million
₩376.59 Billion
≈ $255.21 Million
+11.48pp
2022-12-31 5.64% ₩21.94 Billion
≈ $14.87 Million
₩388.78 Billion
≈ $263.47 Million
+1.28pp
2021-12-31 4.36% ₩27.80 Billion
≈ $18.84 Million
₩636.86 Billion
≈ $431.59 Million
+3.24pp
2020-12-31 1.12% ₩6.71 Billion
≈ $4.55 Million
₩596.91 Billion
≈ $404.52 Million
-21.91pp
2019-12-31 23.04% ₩82.52 Billion
≈ $55.92 Million
₩358.18 Billion
≈ $242.73 Million
-7.37pp
2018-12-31 30.41% ₩113.97 Billion
≈ $77.24 Million
₩374.81 Billion
≈ $254.00 Million
+31.37pp
2017-12-31 -0.96% ₩-1.35 Billion
≈ $-917.17K
₩140.73 Billion
≈ $95.37 Million
-18.49pp
2016-12-31 17.52% ₩34.82 Billion
≈ $23.60 Million
₩198.71 Billion
≈ $134.66 Million
-7.73pp
2012-12-31 25.25% ₩16.00 Billion
≈ $10.85 Million
₩63.38 Billion
≈ $42.95 Million
+5.18pp
2011-12-31 20.07% ₩7.86 Billion
≈ $5.33 Million
₩39.19 Billion
≈ $26.56 Million
-17.18pp
2010-12-31 37.25% ₩14.03 Billion
≈ $9.51 Million
₩37.67 Billion
≈ $25.53 Million
-17.50pp
2009-12-31 54.75% ₩23.42 Billion
≈ $15.87 Million
₩42.78 Billion
≈ $28.99 Million
--
pp = percentage points

About Genexine Inc

KQ:095700 Korea Biotechnology
Market Cap
$87.38 Million
₩128.93 Billion KRW
Market Cap Rank
#19781 Global
#1021 in Korea
Share Price
₩2835.00
Change (1 day)
+1.43%
52-Week Range
₩2195.00 - ₩7100.00
All Time High
₩131402.78
About

Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally. The company develops its products through its hybrid Fc platform, a proprietary technology designed to develop long-acting protein drugs; and the DNA vaccine platform that is used to elicit immune responses… Read more